Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present and participate in the following investor conferences in September.

• Baird 2022 Global Healthcare Conference (New York, NY) on Tuesday, September 13 at 2:35 p.m. ET. This event is closed to conference participants only.
• H.C. Wainwright 24th Annual Global Investment Conference (New York, NY) on Wednesday, September 14 at 12:00 p.m. ET.

Links to each event can be accessed on the Investors & Media page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY^® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABA_A receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005431/en/

Company

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals, Inc.